Report #2827334

Received Feb 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: Dec 20, 2023
Onset: Feb 1, 2025
Days to onset: 409
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

First Dose at pharmacy on Dec 20th 2023 and Took a Second Dose at pharmacy on Feb 1, 2025; Initial report received on 03-Feb-2025. A consumer reported that he received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization on 20-Dec-2023 and received the second dose on 01-Feb-2025. No medical history or concomitant medications were reported. On 20-Dec-2023, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available)]. On 01-Feb-2025, 409 days after receiving the first dose of HEPLISAV-B, the patient received dose 2 of HEPLISAV-B (lot number, expiration date, NDC number, route, and site not reported). The patient was inquiring if he was fully immunized. No adverse reactions were reported. The reporter declined to provide further information. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.